Suppr超能文献

使用片剂或纯粉末对阿托伐他汀临时口服混悬液进行配制及稳定性评估。

Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder.

作者信息

Zaid Abdel Naser, Assali Mohyeddin, Zalmout Samah, Basheer Aseel

机构信息

Department of Pharmacy, An Najah National University, Nablus, Palestine.

Sama Pharmaceuticals Co. Ltd., Nablus, Palestine.

出版信息

Eur J Hosp Pharm. 2017 May;24(3):157-161. doi: 10.1136/ejhpharm-2016-000913. Epub 2016 Jun 15.

Abstract

BACKGROUND

Statins are the first-line therapy for lowering high lipid levels. Atorvastatin calcium (AtC) is the most commonly prescribed statin. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which converts HMG-CoA into mevalonic acid, a cholesterol precursor.

OBJECTIVE

To compound and evaluate the stability of AtC suspension (0.4% w/v) using commercial tablets or pure AtC powder as the source of the active pharmaceutical ingredient.

METHOD

Several AtC suspension formulations were produced using commercial AtC tablets or AtC pure powder as the source of the active ingredient. The most suitable one in terms of general organoleptic properties and dissolution was selected for stability studies. For this purpose, samples of final suspensions were stored at room temperature and in the refrigerator. Assay, pH, organoleptic properties and microbial contamination were evaluated according to the USP specifications. High performance liquid chromatography was used for the analysis and quantification of AtC in the studied samples.

RESULTS

The obtained suspension (S4) had good organoleptic properties. It showed complete dissolution of AtC within 30 min. However, the suspension prepared from crushed tablet (S4) showed a better dissolution profile than that prepared from pure powder (S4). The prepared formula had unchanged pH, which remained around 9.9. S and S formulas were both free from microbial contamination. Both products showed good stability within at least the period of use of the 100 mL AtC bottles.

CONCLUSIONS

AtC extemporaneous suspension was successfully prepared using tablets as a source of AtC or pure AtC powder. However, S4 had a better dissolution profile than S4. This study provides a solution for patients with swallowing difficulties or feeding tubes who are unable to take medicines in solid oral dosage forms. Community pharmacists can prepare the suspension using AtC tablets as the source of the active ingredient.

摘要

背景

他汀类药物是降低高血脂水平的一线治疗药物。阿托伐他汀钙(AtC)是最常用的他汀类药物。它抑制3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶,该酶将HMG-CoA转化为甲羟戊酸,一种胆固醇前体。

目的

以市售片剂或纯AtC粉末作为活性药物成分的来源,制备并评估AtC混悬液(0.4% w/v)的稳定性。

方法

以市售AtC片剂或AtC纯粉末作为活性成分的来源,制备了几种AtC混悬液制剂。根据一般感官性质和溶出度选择最适合的制剂进行稳定性研究。为此,将最终混悬液的样品分别储存在室温下和冰箱中。根据美国药典规范评估含量测定、pH值、感官性质和微生物污染情况。采用高效液相色谱法对研究样品中的AtC进行分析和定量。

结果

所得混悬液(S4)具有良好的感官性质。AtC在30分钟内完全溶解。然而,由压碎片剂制备的混悬液(S4)比由纯粉末制备的混悬液(S4)具有更好的溶出曲线。制备的制剂pH值不变,保持在9.9左右。S4和S4制剂均无微生物污染。两种产品在至少100 mL AtC瓶的使用期内均表现出良好的稳定性。

结论

以片剂或纯AtC粉末作为AtC的来源,成功制备了AtC临时混悬液。然而,S4的溶出曲线比S4更好。本研究为吞咽困难或使用饲管而无法服用固体口服剂型药物的患者提供了一种解决方案。社区药剂师可以使用AtC片剂作为活性成分的来源制备混悬液。

相似文献

3
Stability of extemporaneously prepared sitagliptin phosphate solution.西他列汀磷酸盐溶液的稳定性。
PLoS One. 2022 Mar 16;17(3):e0262068. doi: 10.1371/journal.pone.0262068. eCollection 2022.

本文引用的文献

2
Profile of Jennifer Lippincott-Schwartz. Interview by Tinsley H. Davis.詹妮弗·利平科特-施瓦茨简介。廷斯利·H·戴维斯采访。
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):10881-3. doi: 10.1073/pnas.0905805106. Epub 2009 Jun 30.
8
Medication adherence: factors influencing compliance with prescribed medication plans.
Case Manager. 2005 Mar-Apr;16(2):47-51. doi: 10.1016/j.casemgr.2005.01.009.
9
Early vascular benefits of statin therapy.他汀类药物治疗的早期血管益处。
Curr Med Res Opin. 2003;19(6):540-56. doi: 10.1185/030079903125002225.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验